Fulgent Genetics, Inc. (FLGT)
USD 20.54
(19.07%)
USD 20.54
(19.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 289.21 Million USD | -53.27% |
| 2022 | 618.96 Million USD | -37.64% |
| 2021 | 992.58 Million USD | 135.37% |
| 2020 | 421.71 Million USD | 1196.46% |
| 2019 | 32.52 Million USD | 52.31% |
| 2018 | 21.35 Million USD | 14.03% |
| 2017 | 18.73 Million USD | 2.48% |
| 2016 | 18.27 Million USD | 90.85% |
| 2015 | 9.57 Million USD | 649.3% |
| 2014 | 1.27 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 64.48 Million USD | -8.54% |
| 2024 Q2 | 71.02 Million USD | 10.15% |
| 2023 Q1 | 66.16 Million USD | -2.27% |
| 2023 FY | 289.21 Million USD | -53.27% |
| 2023 Q4 | 70.5 Million USD | -16.75% |
| 2023 Q3 | 84.68 Million USD | 24.81% |
| 2023 Q2 | 67.85 Million USD | 2.55% |
| 2022 Q3 | 105.65 Million USD | -15.71% |
| 2022 FY | 618.96 Million USD | -37.64% |
| 2022 Q1 | 320.26 Million USD | 27.26% |
| 2022 Q2 | 125.34 Million USD | -60.86% |
| 2022 Q4 | 67.7 Million USD | -35.92% |
| 2021 Q4 | 251.67 Million USD | 10.45% |
| 2021 FY | 992.58 Million USD | 135.37% |
| 2021 Q1 | 359.42 Million USD | 21.85% |
| 2021 Q3 | 227.86 Million USD | 48.34% |
| 2021 Q2 | 153.61 Million USD | -57.26% |
| 2020 Q4 | 294.97 Million USD | 190.0% |
| 2020 Q1 | 7.75 Million USD | -7.56% |
| 2020 Q2 | 17.26 Million USD | 122.69% |
| 2020 Q3 | 101.71 Million USD | 489.15% |
| 2020 FY | 421.71 Million USD | 1196.46% |
| 2019 Q2 | 8.42 Million USD | 56.87% |
| 2019 Q3 | 10.34 Million USD | 22.83% |
| 2019 Q4 | 8.38 Million USD | -18.94% |
| 2019 FY | 32.52 Million USD | 52.31% |
| 2019 Q1 | 5.37 Million USD | -5.44% |
| 2018 Q3 | 5.62 Million USD | 4.17% |
| 2018 Q1 | 4.65 Million USD | 8.69% |
| 2018 FY | 21.35 Million USD | 14.03% |
| 2018 Q4 | 5.67 Million USD | 0.96% |
| 2018 Q2 | 5.4 Million USD | 16.05% |
| 2017 Q1 | 5.3 Million USD | -9.36% |
| 2017 FY | 18.73 Million USD | 2.48% |
| 2017 Q4 | 4.28 Million USD | -4.93% |
| 2017 Q3 | 4.5 Million USD | -2.95% |
| 2017 Q2 | 4.64 Million USD | -12.55% |
| 2016 Q3 | 5.01 Million USD | 26.19% |
| 2016 Q1 | 3.44 Million USD | 18.58% |
| 2016 Q2 | 3.97 Million USD | 15.44% |
| 2016 Q4 | 5.85 Million USD | 16.82% |
| 2016 FY | 18.27 Million USD | 90.85% |
| 2015 Q1 | 1.58 Million USD | 0.0% |
| 2015 Q2 | 2.18 Million USD | 37.34% |
| 2015 Q4 | 2.9 Million USD | -0.14% |
| 2015 Q3 | 2.9 Million USD | 33.2% |
| 2015 FY | 9.57 Million USD | 649.3% |
| 2014 FY | 1.27 Million USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -825.511% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -2063.563% |
| Aspira Women's Health Inc. | 9.15 Million USD | -3059.417% |
| Biodesix, Inc. | 49.08 Million USD | -489.185% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -2859.971% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -11320.064% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -11320.064% |
| Bionano Genomics, Inc. | 36.11 Million USD | -700.789% |
| CareDx, Inc | 280.32 Million USD | -3.171% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | -31.587% |
| DarioHealth Corp. | 20.35 Million USD | -1321.054% |
| Exact Sciences Corporation | 2.49 Billion USD | 88.43% |
| Guardant Health, Inc. | 563.94 Million USD | 48.716% |
| ICON Public Limited Company | 8.12 Billion USD | 96.438% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 92.1% |
| Illumina, Inc. | 4.5 Billion USD | 93.579% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -9194.131% |
| iSpecimen Inc. | 9.92 Million USD | -2813.05% |
| Standard BioTools Inc. | 106.34 Million USD | -171.97% |
| MDxHealth SA | 70.19 Million USD | -312.025% |
| 23andMe Holding Co. | 219.63 Million USD | -31.677% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 84.664% |
| Myriad Genetics, Inc. | 678.4 Million USD | 57.368% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -32197.016% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 51.117% |
| Neogen Corporation | 924.22 Million USD | 68.707% |
| Inotiv, Inc. | 572.42 Million USD | 49.476% |
| Natera, Inc. | 1.08 Billion USD | 73.285% |
| OPKO Health, Inc. | 863.49 Million USD | 66.507% |
| Psychemedics Corporation | 22.09 Million USD | -1208.775% |
| Prenetics Global Limited | 21.74 Million USD | -1230.163% |
| Prenetics Global Limited | 21.74 Million USD | -1230.163% |
| Precipio, Inc. | 15.19 Million USD | -1803.093% |
| Personalis, Inc. | 73.48 Million USD | -293.589% |
| RadNet, Inc. | 1.61 Billion USD | 82.11% |
| Sera Prognostics, Inc. | 306 Thousand USD | -94414.052% |
| Sotera Health Company | 1.04 Billion USD | 72.437% |
| Neuronetics, Inc. | 71.34 Million USD | -305.355% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -531.676% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -531.676% |
| Trinity Biotech plc | 56.83 Million USD | -408.891% |
| Twist Bioscience Corporation | 312.97 Million USD | 7.592% |
| Exagen Inc. | 52.54 Million USD | -450.379% |